2024
Unveiling the prognostic significance of malignant ascites in advanced gastrointestinal cancers: a marker of peritoneal carcinomatosis burden
Provenzano L, Gwee Y, Conca V, Lonardi S, Bozzarelli S, Tamburini E, Passardi A, Zaniboni A, Tosi F, Aprile G, Nasca V, Boccaccino A, Ambrosini M, Vetere G, Carullo M, Guaglio M, Battaglia L, Zhao J, Chia D, Yong W, Tan P, So J, Kim G, Shabbir A, Ong C, Casella F, Cremolini C, Bencivenga M, Sundar R, Pietrantonio F. Unveiling the prognostic significance of malignant ascites in advanced gastrointestinal cancers: a marker of peritoneal carcinomatosis burden. Therapeutic Advances In Medical Oncology 2024, 16: 17588359241289517. PMID: 39502404, PMCID: PMC11536604, DOI: 10.1177/17588359241289517.Peer-Reviewed Original ResearchMetastatic colorectal cancerMetastatic gastric cancerMetastatic gastric cancer patientsPeritoneal metastasisMalignant ascitesAdvanced gastrointestinal cancerSurvival outcomesMedian peritoneal cancer index scoreGastrointestinal cancerPeritoneal cancer index scoreGastric cancerMetastatic colorectal cancer patientsSubgroup of patientsMedian OSProgression-freeOverall survivalSystemic therapyPrognostic significancePatient survivalAscites groupPoor outcomeRetrospective analysisColorectal cancerRandomized trialsAscites
2022
Regulatory enhancer profiling of mesenchymal-type gastric cancer reveals subtype-specific epigenomic landscapes and targetable vulnerabilities
Ho S, Sheng T, Xing M, Ooi W, Xu C, Sundar R, Huang K, Li Z, Kumar V, Ramnarayanan K, Zhu F, Srivastava S, Bin Adam Isa Z, Anene-Nzelu C, Razavi-Mohseni M, Shigaki D, Ma H, Tan A, Ong X, Lee M, Tay S, Guo Y, Huang W, Li S, Beer M, Foo R, Teh M, Skanderup A, Teh B, Tan P. Regulatory enhancer profiling of mesenchymal-type gastric cancer reveals subtype-specific epigenomic landscapes and targetable vulnerabilities. Gut 2022, 72: 226-241. PMID: 35817555, DOI: 10.1136/gutjnl-2021-326483.Peer-Reviewed Original ResearchConceptsEpigenomic landscapeGastric cancerEnhancer landscapeGenome-wide epigenomic profilesDownstream targetsPharmacological inhibitionCell linesClinically aggressive subtypeTargetable genomic alterationsMultiple molecular subtypesChIP-seqPoor patient survivalGenomic associationsGC cell linesTranscriptomic scenarioEpigenomic profilingSuper-enhancersChromatin immunoprecipitationRNA sequencingTranscriptome profilingUpstream regulatorGenomic alterationsTherapy resistanceCRISPR/Cas9 editingPatient survival
2019
Evaluation of Electronic Activity Monitors (EAMs) during phase I clinical trials.
Scaranti M, Sundar R, Daly R, Collins D, Dolling D, Gennatas S, Rao Baikady B, Kaye S, Banerji U, Lopez J, De Bono J, Minchom A. Evaluation of Electronic Activity Monitors (EAMs) during phase I clinical trials. Journal Of Clinical Oncology 2019, 37: e18175-e18175. DOI: 10.1200/jco.2019.37.15_suppl.e18175.Peer-Reviewed Original ResearchPhase I trialI trialMean step countPhase I clinical trialPatient's physical functionHeart ratePredicting patient survivalDrug Development UnitStep countsECOG PSPhysical functionPatient survivalElectronic activity monitorsMedical oncologistsRecord heart ratePatient groupPhysician biasTreatment cyclesTreatment decisionsPatientsActivity monitoringPatient outcomesStatistical significanceOSPhysicians